| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-46 |
| filingDate |
1991-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7366465c88d2a6693cf2ce586402ad3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f0e25b4bfc379bc990d688b713a0387
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87785ff8e004f732d87c538d39edd8f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67c980aecd272966f0f8a2b32ebc03b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_284f68e98f759c4a3c3c669923d6a45c |
| publicationDate |
1991-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2039540-A1 |
| titleOfInvention |
Modified beta adrenergic receptor |
| abstract |
TITLE OF THE INVENTION MODIFIED BETA ADRENERGIC RECEPTOR ABSTRACT OF THE DISCLOSURE A Modified Beta Adrenergic Receptor having the amino acid residue in position 113 (aspartic acid) substituted by a serine residue has been synthesized. This modified receptor interacts with novel ligands that do not react with the natural Asp 113 containing receptor. Transgenic animals containing this modified receptor will respond to novel ligands which will not interact with the normal receptor. |
| priorityDate |
1990-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |